Janney starts Abcam at buy; fair value estimate £17

Janney Montgomery Scott initiated coverage of Abcam plc (LSE:ABC) with a “buy” rating and fair value estimate of £17. The stock closed at £14.72 on July 1.

Abcam is a world leader in research antibodies, with the largest product line-up and a website providing unparalleled reference documentation.

“We believe that the antibody market and revenue at industry leaders like Abcam and [competitor] Bio-Techne are at an inflection point of higher growth,” writes analyst Paul Knight.

Driving increased growth is the faster rate of gene sequencing driving more biomarker research; new generations of high-throughput instrument technologies using antibodies as detection elements; increased U.S. academic funding; and the growth in Asian biomedical research activity, he added.

Mr. Knight cited increasing visibility of revenue, upper-end of industry operating margins, a pristine balance sheet, and potentially more M&A for his recommendation of Abcam.

Sign up for the BioTuesdays weekly newsletter

Get the latest news on the healthcare industry’s corporate and clinical developments, executive moves, and market updates. Every Tuesday, in your inbox.